Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas.  

Highlights

•  Outcomes for pediatric/AYA sarcoma patients are poor and no targeted treatments exist.
•  Pediatric and AYA sarcoma patients rarely harbor actionable genomics aberrations.
•  Phosphoproteomics captured novel actionable drivers missed by genomics screens

•  Phosphoproteomics explained critical targeted drug mechanism of action/resistance.

•  Outcomes in personalized medicine platforms may be enhanced by phosphoproteomics.

Press the link below to read more:

https://www.sciencedirect.com/science/article/pii/S0304419X21001116

Powered by WordPress | Theme: Astrid by aThemes.